Financial equity research analysts covering Integra LifeSciences maintain consensus 12-month average price targets generally clustering in the upper teens range. Analysts weigh the company's long-term growth catalysts in specialty surgical devices and tissue technologies against near-term headwinds related to facility remediation timelines, manufacturing output restorations, and variable quarterly profitability margins reported across global healthcare markets.
Stuart M. Essig serves as the President and Chief Executive Officer of Integra LifeSciences, having stepped back into the executive leadership role to guide the company through its next strategic phase.
Financial equity research analysts covering Integra LifeSciences maintain a generally neutral consensus rating, with most 12-month average price targets hovering around the eighteen to nineteen dollar range.
Compensation packages for Vice President-level executives at major medical technology firms like Integra LifeSciences typically comprise a substantial base salary, annual performance-based cash bonuses, and long-term equity incentives such as restric...
Smith+Nephew did not acquire the entire Integra LifeSciences enterprise, but it did successfully complete the acquisition of Integra's Extremity Orthopaedics business for two hundred and forty million dollars in cash.
Integra LifeSciences generates annual revenues hovering around one billion four hundred million dollars to one billion five hundred million dollars.
Evaluating whether Integra LifeSciences is a solid corporate entity involves weighing its strong market positioning in neurosurgery and regenerative wound care against ongoing operational challenges and quality remediation execution.
Integra LifeSciences operates as a mid-cap medical technology organization with an annual revenue generation hovering around one billion four hundred million to one billion five hundred million dollars.
Integra LifeSciences operates through several key domestic and international subsidiaries and operating units that handle its specialized manufacturing, global distribution, and regional commercial activities.
Integra products are utilized extensively across neurosurgery, reconstructive surgery, and advanced wound care applications.
The total market capitalization of Integra LifeSciences fluctuates continuously during active market trading sessions based on its share price and total outstanding common stock, generally resting in the range of one billion to one and a half billion...
Integra LifeSciences has implemented targeted workforce reductions and operational restructuring initiatives in response to facility optimizations and quality system remediation programs.
Integra LifeSciences completed a landmark acquisition of Johnson & Johnson's Codman Neurosurgery business for approximately one billion and forty-five million dollars.
The executive leadership team of Integra LifeSciences features seasoned professionals with extensive experience in the medical device and healthcare industries. Stuart M.
Integra LifeSciences Holdings Corporation is a publicly traded enterprise listed on the NASDAQ stock exchange under the ticker symbol IART, meaning its ownership is broadly distributed among thousands of institutional asset management firms, mutual f...
Integra LifeSciences employs approximately 4,300 to 4,500 personnel globally across its corporate headquarters, research and development laboratories, and manufacturing facilities.
Whether Integra LifeSciences represents a favorable stock purchase depends heavily on an investor's risk tolerance and time horizon.
Integra LifeSciences specializes in a diverse portfolio of advanced medical technologies, surgical instruments, and tissue regeneration products designed for neurosurgery, reconstructive surgery, and general wound care.
Employee reviews and corporate workplace assessments for Integra LifeSciences generally highlight a collaborative culture, meaningful engagement within the mission-driven medical technology sector, and opportunities for professional growth in enginee...
Integra LifeSciences Holdings Corporation is a prominent multinational medical technology enterprise specializing in the research, development, manufacturing, and distribution of innovative surgical instruments, neurosurgical devices, and advanced ti...
The corporate headquarters of Integra LifeSciences is officially located in Princeton, New Jersey, United States.
Integra LifeSciences exhibits steady strategic evolution and product pipeline expansion, though its financial growth has experienced short-term fluctuations due to targeted manufacturing facility optimizations, quality system remediation efforts, and...
The primary product categories driving Integra LifeSciences' commercial revenue include Codman specialty surgical tools, dural repair membranes, precision neurosurgery equipment, advanced tissue ablation systems, and regenerative wound care solutions...
Integra LifeSciences Holdings Corporation is a publicly traded enterprise listed on the NASDAQ stock exchange under the ticker symbol IART, meaning its ownership is broadly distributed among thousands of institutional asset management firms, mutual f...
Integra LifeSciences Holdings Corporation is a publicly traded enterprise listed on the NASDAQ stock exchange under the ticker symbol IART, meaning its ownership is broadly distributed among thousands of institutional asset management firms, mutual f...
The total corporate market capitalization of Integra LifeSciences fluctuates continuously during active market trading sessions based on its share price and total outstanding common stock, generally resting in the range of one billion to one and a ha...